MICHEL FRANCOIS GILLIET, M.D.
Dermatology at Holcombe Blvd, Houston, TX

2009015, Jun 18, 2009

Sep 30, 2005

11/664869

Michel Gilliet - Houston TX, US
Frank O. Nestle - London, GB

A61K 39/395, C07K 16/24, C07K 14/715, C07H 21/02, A61P 17/06

4241581, 5303892, 530350, 536 245

The discovery of plasmacytoid dendritic cell precursors (PDC) as crucial effector cells with high production of type I interferons (IFNs) in early psoriasis development has led to the present invention that blocking of type I IFNs can be used for prevention and therapy of psoriasis. The invention relates to the use of a type I interferon blocking agent, such as a type I IFN antagonist (e.g. an anti-IFN-α antibody) or type I IFN receptor antagonist, for the preparation of a medicament for the prevention and treatment of psoriasis, and to a method of prevention and treatment of psoriasis using a type I interferon blocking agent.